Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

Experimental Neurology

Volumn 162, Issue 2, 2000, Pages 321-327

  Kanda, Tomoyuki ^a,b   Jackson, Michael J ^b   Smith, Lance A ^b   Pearce, Ronald K B ^b   Nakamura, Joji ^a   Kase, Hiroshi ^a   Kuwana, Yoshihisa ^a,b   Jenner, Peter ^b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine A(2A) antagonist; Antiparkinson; Dyskinesia; L DOPA; MPTP; Primates

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE A2 RECEPTOR ANTAGONIST; CARBIDOPA; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ISTRADEFYLLINE; LEVODOPA; QUINPIROLE; SKF 80723; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RECEPTOR BLOCKING;

EID: 0034049544     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7350     Document Type: Article

References (34)

1. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv. Neurol. 45:1987;1-18.
2. Hornykiewicz O., Kish S. J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34.
3. Kurlan R. Practical therapy of Parkinson's disease. Semin. Neurol. 7:1987;160-166.
4. Mouradian M. M., E. I. J., Baronti F., Fabbrini G., Juncos J. L., Chase T. N. Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 25:1989;523-526.
5. Kurth M. C., Adler C. H. COMT inhibition: A new treatment strategy for Parkinson's disease. Neurology. 50:1998;S3-S14.
6. Goetz C. G. Influence of COMT inhibition on levodopa pharmacology and therapy. Neurology. 50:1998;S26-S30.
7. Jorga K., Fotteler B., Sedek G., Nielsen T., Aitken J. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J. Neurol. 245:1998;223-230.
8. Ann. Neurol. 42:1997;747-755.
9. Verhagen-Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M. M., Chase T. N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323-1326.
10. Daly J. W., Butts-Lamb P., Padgett W. Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines. Cell. Mol. Neurobiol. 3:1983;69-80.
11. 3H]NECA in rat striatal membranes. Mol. Pharmacol. 29:1986;331-346.
12. Fredholm B. B., Abbracchio M. P., Burnstock G., Daly J. W., Harden T. K., Jacobson K. A., Leff P., Williams M. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 46:1994;143-156.
13. 3H]CGS 21680. Eur. J. Pharmacol. 168:1989;243-246.
14. 2 receptor mRNA in the human brain. Neurosci. Lett. 130:1989;177-181.
15. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57:1991;1062-1067.
16. 2 receptors induces catalepsy. Neurosci. Lett. 130:1991;162-164.
17. 2A receptor antagonist with anticataleptic activity. Eur. J. Pharmacol. 256:1994;263-268.
18. Fuxe K., Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: Considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med. Biol. 52:1974;48-54.
19. Brown S. J., Gill R., Evenden J. L., Iversen S. D., Richardson P. J. Striatal A2 receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation. Psychopharmacology. 103:1991;78-82.
20. Josselyn S. A., Beninger R. J. Behavioral effects of intrastriatal caffeine mediated by adenosinergic modulation of dopamine. Pharmacol. Biochem. Behav. 39:1991;97-103.
21. Vellucci S. V., S. D. J., Richardson P. J. Adenosine A2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology. 111:1993;383-388.
22. 2 antagonists. J. Med. Chem. 35:1992;2342-2345.
23. 2 receptor antagonist. Eur. J. Pharmacol. 267:1994;335-341.
24. 2 antagonist with anti-cataleptic activity. Bioorg. Med. Chem. Lett. 7:1997;2349-2352.
25. 2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann. Neurol. 43:1998;507-513.
26. Loschmann P. A., Smith L. A., Lange K. W., Jahnig P., Jenner P., Marsden C. D. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP treated common marmosets. Psychopharmacology. 109:1992;49-56.
27. Pearce R. K. B., Jackson M. J., Smith L. A., Jenner P., Marsden C. D. Chronic l-DOPA administration induces dyskinesias in the MPTP-treated common marmoset (Callithrix Jacchus). Move. Disord. 10:1995;731-740.
28. Gnanalingham K. K., Erol D. D., Hunter A. J., Smith L. A., Jenner P., Marsden C. D. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology. 117:1995;275-286.
29. 2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport. 9:1998;2857-2860.
30. 2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience. 42:1991;697-706.
31. 2A antagonists as new agents for the treatment of Parkinsona's disease. Trends Pharmacol. Sci. 18:1997;338-344.
32. 2a receptor-mediated modulation of striatal GABA and ACh release. Br. J. Pharmacol. 113:1994;43-48.
33. 2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 16:1996;605-611.
34. 2a receptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. 66:1996;1882-1888.